---

Ibrutinib + Rituximab in Sclerotic Chronic Graft-Versus-Host Disease (cGVHD)

Background: Sclerotic cGVHD

• Dermal sclerosis with thickened collagen bundles (histologically similar to morphea/systemic sclerosis)
• Fasciitis, restricted joint range-of-motion, and deep tissue tethering
• Eosinophilic fasciitis-like involvement visible on MRI as fascial edema
• High morbidity, often steroid-refractory, and associated with major functional impairment

---

Mechanisms of Action

Ibrutinib (BTK Inhibitor)

• Irreversibly inhibits Bruton's tyrosine kinase (BTK) in B cells and ITK (IL-2-inducible T-cell kinase) in T cells
• Dual blockade suppresses:
  • B-cell differentiation, autoantibody production, and BAFF-driven B-cell survival
  • Th2 and Th17 T-cell differentiation (via ITK inhibition)
  • TGF-beta signaling pathways implicated in fibrogenesis
• Reduces the B-cell autoantibody load that perpetuates sclerosis in cGVHD

Rituximab (Anti-CD20 mAb)

• Depletes CD20+ B cells via complement-dependent cytotoxicity, ADCC, and apoptosis
• Interrupts antigen presentation by B cells to alloreactive T cells
• Patients with higher circulating activated B cells respond particularly well
• Lower CD5+ B-cell counts at baseline predict better response - a proposed biomarker for patient selection

---

Rationale for Combination (Ibrutinib + Rituximab)

---

Clinical Evidence

Ibrutinib Monotherapy (Foundation Data)

• Overall response rate (ORR): 69% (31% CR, 38% PR) at median 26-month follow-up
• Sclerotic subgroup (n=18): 61% showed sclerotic response (39% CR, 22% PR) - this is a particularly notable finding given that sclerotic disease is classically considered the most refractory subtype
• Sustained responses at ≥20 weeks: 69% of responders; ≥44 weeks: 55%
• Multi-organ responses: 73% with ≥2 organs involved showed responses in ≥2 organs
• Corticosteroid reduction: 64% reached <0.15 mg/kg/day; 8 patients discontinued steroids entirely
• This led to FDA approval (2017) of ibrutinib for steroid-refractory cGVHD [PMID: 31260802]

Rituximab in Sclerotic cGVHD

• ORR: 71% (2 CR, 15 PR)
• Complete resolution of ulcers in 2/5 patients with severe ulcerations

• 50% corticosteroid dose reduction in the majority of responders

• CD5+ B-cell count at baseline was significantly lower in responders (p=0.007) - proposed as a biomarker guiding treatment selection
• Responses were durable through end of study follow-up

Ibrutinib + Rituximab: Direct Evidence

1. Complementary mechanisms with non-overlapping toxicity profiles
2. Strong single-agent data for both drugs in sclerotic cGVHD
3. Analogy to ibrutinib + rituximab synergy in B-cell malignancies (CLL, Waldenstrom's), where rituximab adds depth of B-cell depletion to ibrutinib's inhibitory effects
4. Ongoing Phase 2 clinical trials investigating ibrutinib-based combinations in cGVHD

---

Current Positioning in Treatment Algorithm

1. First-line: Systemic corticosteroids (prednisone ≤1 mg/kg/day)
2. Steroid-refractory/dependent: Ruxolitinib (JAK1/2 inhibitor) - now preferred over ibrutinib as second-line after REACH3 trial data
3. Ibrutinib: FDA-approved for SR-cGVHD; particularly considered in patients with sclerotic manifestations or B-cell-driven disease features
4. After ≥2 prior lines: Belumosudil (ROCK2 inhibitor, ORR >70%)
5. Rituximab: Used as an adjunctive/combination agent, particularly for sclerotic cGVHD where B-cell depletion is a priority
6. Ibrutinib + Rituximab: Rational combination used in refractory sclerotic disease; no dedicated RCT yet but supported by mechanistic rationale and single-agent trial data

• Dermatology 2-Volume Set 5e (Bolognia), p. 999-1000

---

Sclerotic cGVHD - Additional Management Considerations

• Physical therapy: Mandatory for joint range-of-motion preservation in sclerotic involvement
• Phototherapy: PUVA ± retinoids, UVA1 - improve sclerotic changes with limited evidence
• Imatinib: Another TKI with anti-fibrotic activity via PDGFR inhibition; used in sclerotic/fasciitic cGVHD
• Extracorporeal photopheresis (ECP): Modulates Th2/Treg balance; useful adjunct in cutaneous sclerotic disease
• Topical agents: Adjunctive only; tacrolimus, corticosteroids for lichenoid component

---

Toxicity Profile of the Combination

---

Summary

• Ibrutinib targets both the B-cell and T-cell/fibrotic arms of cGVHD pathogenesis via BTK and ITK inhibition, with documented 61% response rate in sclerotic disease
• Rituximab provides direct B-cell depletion, reducing the autoantibody burden driving sclerosis, with 71% ORR in the rituximab + nilotinib sequential trial
• The combination is used in clinical practice for multi-refractory sclerotic cGVHD, though a dedicated prospective RCT of this specific pairing has not yet been published
• CD5+ B-cell count may serve as a predictive biomarker for rituximab response, potentially helping select patients most likely to benefit from this combination

---

Ibrutinib vs Imatinib vs Nilotinib for Sclerotic cGVHD

1. Mechanisms of Action (Target Profiles)

---

2. Clinical Evidence - Response Rates

Ibrutinib (FDA-approved)

• Waller et al., 2019 - Phase 1b/2 1-year update [PMID: 31260802]

Imatinib

• Baek et al., 2022 - Multicenter Phase II [PMID: 35861214]
• Choi et al., 2021 - Pediatric imatinib+MMF [PMID: 34314892]

Nilotinib

• Srour et al., 2023 - Nilotinib after imatinib failure [PMID: 36624161]

---

3. Real-World Head-to-Head Comparison (Best Available Data)

---

4. Systematic Review Perspective (Highest-Level Evidence)

• Ruxolitinib was the only agent with statistically significant benefit in RCT evidence (ORR 41.5%, BSA reduction from 14.5% to 6.2%)
• Imatinib was included but did not demonstrate statistically significant benefit versus comparator in the RCT reviewed
• Ibrutinib: In the ibrutinib-prednisone RCT, no statistically significant advantage vs placebo for cutaneous endpoints
• Entospletinib was inferior to placebo
• Neither imatinib nor ibrutinib cleared the bar of high-level RCT evidence for cutaneous cGVHD

---

5. Tolerability Comparison

---

6. Practical Positioning in Sclerotic cGVHD

Steroid-refractory sclerotic cGVHD
│
├── Preferred 2nd line: Ruxolitinib (only drug with RCT evidence; FDA-approved)
│
├── Consider for fibrotic/sclerotic-predominant disease:
│   ├── Imatinib 100-400 mg/day (PDGFR-driven fibrosis; 71% FFS at 12m; dose-titrate carefully)
│   └── Ibrutinib 420 mg/day (FDA-approved; B-cell + T-cell + fibrosis; 61% sclerotic ORR;
│                              but 46% FFS; higher discontinuation)
│
├── Combination approach:
│   └── Rituximab → Nilotinib sequential (71% ORR in sclerotic; best for B-cell-driven disease)
│
└── Nilotinib monotherapy / after imatinib failure: Avoid (21% ORR; high discontinuation)

---

7. Summary Comparison Table

• Ibrutinib is the only FDA-approved option; best for patients with mixed B-cell + T-cell disease and multi-organ involvement, but has lower FFS and higher discontinuation
• Imatinib has the best long-term failure-free survival in real-world data (71% FFS), making it a practical choice for fibrotic/sclerotic predominant disease - dose-titrate from 100 mg to minimize toxicity
• Nilotinib has the most potent anti-fibrotic mechanism but performs disappointingly as standalone salvage after imatinib failure; its best role is in the rituximab + nilotinib sequential regimen specifically designed for sclerotic cGVHD